Skip to content

Cayenne Pepper Cataplasm - Safety Study

Cayenne Pepper Cataplasm Application and Potential Side Effects

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03440125
Acronym
Munari04
Enrollment
30
Registered
2018-02-20
Start date
2016-03-15
Completion date
2016-12-15
Last updated
2018-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Back Pain

Keywords

Low Back Pain, Capsicum, Physical Therapy, Pain

Brief summary

The beneficial analgesic effects of Rubefacenciae (redden skin substances), is known since 1830 as a treatment for pain, cramps, and disorders of the musculoskeletal system. Herbal cataplasms containing rubefacient substances, such as Cayenne pepper, are commonly used as natural medications to treat painful or aching areas in the case of acute or chronic back pain, and rheumatisms. In Vienna and lower Austria, a Cayenne Pepper Cataplasm (CPC) application containing Cayenne pepper and Kaolin powder in mixed proportion, is commonly used to treat musculoskeletal conditions of pain especially of the low back. However, a concern about the safety of such applications was recently raised. Therefore, the aims of the present study are to evaluate the effects of 10x 20min CP cataplasm application as a single treatment or in combination with electrical stimulation and massage on selected functional and molecular parameters on i) healthy subjects and ii) subjects suffering from low back pain.

Detailed description

Musculoskeletal diseases, such as neck and low back pain, are widespread disorders in many developed countries. Their management is challenging, and it may have mounting socioeconomic burden. Several evidences in the literature demonstrate the efficacy of many therapeutic strategies in the treatment of these conditions, based on pharmacological or surgical interventions. Physical medicine therapies are good alternatives that may have beneficial effects, especially when used as first line of intervention before approaching more expensive pharmacological or invasive medications. The beneficial analgesic effects of Applicatio Epispasticorum of Rubefacenciae (redden skin substances), is known since 1830 as a treatment for pain, cramps, and disorders of the musculoskeletal system. Herbal cataplasms containing rubefacient substances, such as Cayenne pepper (CP), are commonly used as natural medications to treat painful or aching areas in the case of acute or chronic back pain, and rheumatisms. They are also used in pain involving joints caused by osteoarthritis. A galenic preparation composed of rubefacient substances of vegetable origin, which generated vasodilation and increase in blood circulation on the treated areas, was first prescribed in 1909 by Dr. Giuseppe Munari to treat pain of various areas of the locomotive system. He proposed a method based on applications prepared according to his own galenic formula that have become famous all over Italy and Europe. In Vienna and lower Austria, a Munari-like application containing CP and Kaolin powder in mixed proportion, is commonly used to treat musculoskeletal conditions of pain especially of the low back. The research on responses to CPC applications, particularly in combination with other modalities is scarce. Therefore, the aims of the present study are firstly to evaluate the effects of 10x 20min CP cataplasm application on selected functional and molecular parameters on healthy subjects. Then, the same applications will be used on subjects suffering from low back pain (LBP) - both as a single treatment and in combination with electrical stimulation and massage.

Interventions

DRUGCayenne Pepper topical

20min topical Cayenne Pepper Cataplasm application containing 5% Cayenne Pepper nd 95% Kaolin mixed with water

DEVICEElectrical stimulation

Electrical stimulation 10min 60Hz biphasic rectangular neuromuscular electrical Stimulation (NMES)

PROCEDUREMassage

10 minutes of classical massage of low back pain area.

Sponsors

S2P, Science to Practice, Ltd.
CollaboratorOTHER
Comenius University
CollaboratorOTHER
Wilhelminenspital Vienna
CollaboratorOTHER
Ludwig Boltzmann Institute of Electrical Stimulation and Physical Rehabilitation
CollaboratorOTHER
University of Primorska
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Chronic low back pain (\>3 months) * Body mass index below 35 kg/mˇ2

Exclusion criteria

* pregnancy * sensibility disorders (e.g. due to neurological disease) * injuries, open wounds or rash in intervention area * known hypersensitivity against the applied substances * HIV, Hepatitis C and other due blood communicable infectious diseases

Design outcomes

Primary

MeasureTime frameDescription
Change in concentration of circulating biomarkers of inflammation, neudroendocrine stress and blood vessel activationBefore the application, 45 minutes after 10th application and 48 hours after 10th applicationThe blood analysis will include standard analysis of hemogram, C-reactive proteins, creatine-kinase, sedimentation, albumin and cortisol. Enzyme-linked immunosorbent assay (ELISA) will include Tumor necrosis factor-Alpha, Interleukin-6, Leukotriene B4 and P-Selectine. Additionally, microRNA analysis will be performed (gene numbers: 1, 21, 23, 25, 103, 126, 133, 146, 155, 199a, 199b, 191, 206, 451.
Change in systolic and diastolic blood pressureBefore the application, 45 minutes after 10th application and 48 hours after 10th applicationSystolic and diastolic blood pressure \[mmHg\], measured at both sides of the body with blood pressure gauge
Heart rateBefore the application, 45 minutes after 10th application and 48 hours after 10th applicationHeart rate (bpm), measured with heart rate monitor belt.

Secondary

MeasureTime frameDescription
Oswestry disability index (ODI)Before the application, 45 minutes after 10th application and 48 hours after 10th applicationODI will be used only in LBP arms (Arm 2 and 3). ODI is commonly used by clinicians and researchers to quantify disability for low back pain.
Skin Sensory FunctionBefore the application, 45 minutes after 10th application and 48 hours after 10th applicationSkin sensory function will be assessed by 2-point discrimination test (which is carried out using two pins, oriented in medial-lateral direction and pressed perpendicularly to the skin, with the medial pin being 3 cm laterally from the L3 spinal process. The subject is asked to report whether he/she felt one or two pins) and mono filament/light touch sensitivity tests (monofilaments calibrated to 0.025, 0.07, 2, 5, and 10 grams The subject is asked to report when he/she felt touching the skin with a monofilament 3 cm laterally from L3 spinal process). The lightest mono filament and the lowest pin inter-distance are take as final outcome measures.
36-Item Short Form Survey (SF-36)Before the application, 45 minutes after 10th application and 48 hours after 10th applicationThe Short Form (36) Health Survey (SF-36) is a patient-reported survey of patient health. It consists of eight scaled scores, which are the weighted sums all questions in their respective section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the higher is the disability.
Skin TemperatureBefore the application, 45 minutes after 10th application and 48 hours after 10th applicationSkin temperature \[°C\] at the site of application (low back) and at the control part of the body (neck), measured with a laser thermometer.
FlexibilityBefore the application, 45 minutes after 10th application and 48 hours after 10th applicationAssessment of total spine flexibility (forward bend test) and separately for the lumbar part (Schober's test) and thoracic part.
Change in pain perceptionBefore the application, 45 minutes after 10th application and 48 hours after 10th applicationPain perception during rest and movement assessed with visual analogue scale (0-10). 0 represents no pain, and 10 represents severe pain.
EQ-5D- 5L questionnaireBefore the application, 45 minutes after 10th application and 48 hours after 10th applicationEQ-5D- 5L questionnaire includes following aspects: mobility, care, usual activities, pain/discomfort, anxiety/depression, crosswalk-index, self-feeling of health. Each aspect is evaluated on a 1-5 scale, with following descriptions of levels: having no problems, having slight problems, having moderate problems, having severe problems and being unable to do/having extreme problems. Visual analogue scale is the second part of the questionnaire, asking to mark health status on the day of the interview on a 20 cm vertical scale with end points of 0 and 100. There are notes at the both ends of the scale that the bottom rate (0) corresponds to the worst health you can imagine, and the highest rate (100) corresponds to the best health you can imagine.

Countries

Slovakia, Slovenia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026